ArQule Company Profile (NASDAQ:ARQL)

About ArQule (NASDAQ:ARQL)

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARQL
  • CUSIP: 04269E10
  • Web: www.arqule.com
Capitalization:
  • Market Cap: $91.07 million
  • Outstanding Shares: 71,146,000
Average Prices:
  • 50 Day Moving Avg: $1.21
  • 200 Day Moving Avg: $1.22
  • 52 Week Range: $0.92 - $1.82
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.12
  • P/E Growth: -0.59
Sales & Book Value:
  • Annual Revenue: $3.48 million
  • Price / Sales: 26.17
  • Book Value: $0.24 per share
  • Price / Book: 5.33
Profitability:
  • EBIDTA: ($25,050,000.00)
  • Net Margins: -482.44%
  • Return on Equity: -95.33%
  • Return on Assets: -66.00%
Debt:
  • Debt-to-Equity Ratio: 0.84%
  • Current Ratio: 5.33%
  • Quick Ratio: 5.33%
Misc:
  • Average Volume: 135,778 shs.
  • Beta: 1.48
  • Short Ratio: 9.07
 

Frequently Asked Questions for ArQule (NASDAQ:ARQL)

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.00. ArQule had a negative net margin of 482.44% and a negative return on equity of 95.33%. During the same period in the prior year, the company posted ($0.08) earnings per share. View ArQule's Earnings History.

When will ArQule make its next earnings announcement?

ArQule is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for ArQule.

Who are some of ArQule's key competitors?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:

  • Patrick J. Zenner, Independent Chairman of the Board
  • Peter S. Lawrence, President, Chief Operating Officer
  • Paolo Pucci, Chief Executive Officer, Director
  • Robert J. Weiskopf, Chief Financial Officer, Treasurer
  • Brian Schwartz M.D., Chief Medical Officer
  • Timothy C. Barabe, Independent Director
  • Susan L. Kelley M.D., Independent Director
  • Ronald M. Lindsay Ph.D., Independent Director
  • Michael D. Loberg Ph.D., Independent Director
  • William G. Messenger D. Min., Independent Director

How do I buy ArQule stock?

Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ArQule stock can currently be purchased for approximately $1.28.


MarketBeat Community Rating for ArQule (NASDAQ ARQL)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  129
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50N/AView Rating Details
12/27/2015Royal Bank Of CanadaUpgradeBuyN/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for ArQule (NASDAQ:ARQL)
Earnings by Quarter for ArQule (NASDAQ:ARQL)
Earnings History by Quarter for ArQule (NASDAQ ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017($0.11)N/AView Earnings Details
5/3/2017Q1 2017($0.11)($0.11)ViewListenView Earnings Details
3/7/2017Q4 2016($0.10)($0.10)$1.20 million$1.19 millionViewListenView Earnings Details
11/7/2016Q316($0.09)($0.08)$1.10 million$1.22 millionViewListenView Earnings Details
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.13)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ArQule (NASDAQ:ARQL)
2017 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ArQule (NASDAQ:ARQL)
Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 60.55%
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ArQule (NASDAQ:ARQL)
Latest Headlines for ArQule (NASDAQ:ARQL)
Source:
DateHeadline
rttnews.com logoArQule: First Patient Dosed In ARQ 531 Phase 1 Trial For B-cell Malignancies
www.rttnews.com - July 12 at 1:40 AM
finance.yahoo.com logoArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies
finance.yahoo.com - July 11 at 3:38 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 26 at 4:08 PM
streetinsider.com logoArQule (ARQL) Presents Preclinical Data for BTK Inhibitor, ARQ 531, at EHA
www.streetinsider.com - June 24 at 8:48 PM
finance.yahoo.com logoArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
finance.yahoo.com - June 23 at 4:15 PM
finance.yahoo.com logoArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
finance.yahoo.com - June 7 at 3:50 PM
americanbankingnews.com logo Analysts Expect ArQule, Inc. (ARQL) to Announce -$0.11 EPS
www.americanbankingnews.com - June 5 at 7:37 AM
finance.yahoo.com logoArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 3 at 3:40 PM
finance.yahoo.com logoArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - June 3 at 3:40 PM
baystreet.ca logoArQule Stock Up 28% on Lab Data for B-Cell Lymphoma Drug
www.baystreet.ca - May 19 at 9:27 AM
finance.yahoo.com logoArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
finance.yahoo.com - May 18 at 12:06 PM
finance.yahoo.com logoArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 8:40 PM
americanbankingnews.com logoArQule, Inc. (ARQL) Short Interest Update
www.americanbankingnews.com - May 15 at 8:48 AM
americanbankingnews.com logo-$0.11 EPS Expected for ArQule, Inc. (ARQL) This Quarter
www.americanbankingnews.com - May 9 at 6:16 PM
americanbankingnews.com logoLeerink Swann Brokers Cut Earnings Estimates for ArQule, Inc. (ARQL)
www.americanbankingnews.com - May 8 at 8:26 AM
americanbankingnews.com logoArQule, Inc. (ARQL) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 4 at 7:06 PM
finance.yahoo.com logoEdited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT
finance.yahoo.com - May 4 at 1:47 AM
americanbankingnews.com logoArQule, Inc. (ARQL) Issues Earnings Results, Meets Expectations
www.americanbankingnews.com - May 3 at 12:33 PM
finance.yahoo.com logoArqule Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 9:55 AM
finance.yahoo.com logoArQule reports 1Q loss
finance.yahoo.com - May 3 at 9:55 AM
finance.yahoo.com logoInvestor Network: ArQule, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 9:55 AM
americanbankingnews.com logoArQule (ARQL) Earns Daily Media Impact Rating of 0.13
www.americanbankingnews.com - May 2 at 8:16 AM
americanbankingnews.com logoArQule, Inc. (ARQL) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 1 at 11:56 AM
americanbankingnews.com logoArQule (ARQL) Receiving Somewhat Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 27 at 4:38 PM
finance.yahoo.com logoArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
finance.yahoo.com - April 26 at 9:10 AM
americanbankingnews.com logoArQule (ARQL) Earning Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - April 20 at 2:42 PM
finance.yahoo.com logoArQule To Report First Quarter 2017 Financial Results On May 3, 2017
finance.yahoo.com - April 19 at 9:15 AM
americanbankingnews.com logo-$0.10 EPS Expected for ArQule, Inc. (ARQL) This Quarter
www.americanbankingnews.com - April 18 at 10:21 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Impact ArQule (ARQL) Stock Price
www.americanbankingnews.com - April 17 at 12:07 PM
americanbankingnews.com logoSomewhat Critical Press Coverage Somewhat Likely to Effect ArQule (ARQL) Share Price
www.americanbankingnews.com - April 14 at 7:58 AM
streetinsider.com logoArQule (ARQL) Announces IND Application for BTK Inhibitor ARQ 531 Cleared by FDA - StreetInsider.com
www.streetinsider.com - April 11 at 8:03 AM
finance.yahoo.com logoArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
finance.yahoo.com - April 11 at 8:03 AM
finance.yahoo.com logoETFs with exposure to ArQule, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:07 AM
rttnews.com logoFDA Nod For TSRO, Déjà Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz - RTT News
www.rttnews.com - March 28 at 3:38 PM
finance.yahoo.com logoArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017
finance.yahoo.com - March 28 at 10:32 AM
streetinsider.com logoPre-Open Movers 03/27: (HTGM) (WFT) (SNAP) Higher; (FOMX) (ARQL) (MEET) Lower (more...)
www.streetinsider.com - March 27 at 3:42 PM
us.rd.yahoo.com logoArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
us.rd.yahoo.com - March 27 at 8:30 AM
americanbankingnews.com logoZacks: ArQule, Inc. (ARQL) Given $1.30 Consensus Price Target by Analysts
www.americanbankingnews.com - March 23 at 10:43 AM
finance.yahoo.com logoARQULE INC Financials
finance.yahoo.com - March 15 at 3:54 PM
biz.yahoo.com logoARQULE INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 9 at 9:15 PM
finance.yahoo.com logoEdited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT
finance.yahoo.com - March 8 at 1:41 AM
rttnews.com logoEARNINGS SUMMARY: Details of ArQule Inc. Q4 Earnings Report
www.rttnews.com - March 7 at 3:40 PM
seekingalpha.com logoArQule's (ARQL) CEO Paolo Pucci on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 7 at 3:40 PM
us.rd.yahoo.com logoArQule Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 7 at 3:40 PM
biz.yahoo.com logoQ4 2016 ArQule Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 7 at 3:40 PM
biz.yahoo.com logoARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 7 at 8:28 AM
finance.yahoo.com logoArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
finance.yahoo.com - February 24 at 12:37 PM
investopedia.com logoArQule Liver Cancer Drug Fails Phase 3 (ARQL)
www.investopedia.com - February 20 at 3:32 PM
investopedia.com logoArQule Liver Cancer Drug Fails Phase 3 Trial
www.investopedia.com - February 20 at 3:32 PM
streetinsider.com logoArQule (ARQL), Daiichi Sankyo Phase 3 Study of Tivantinib Misses ... - StreetInsider.com
www.streetinsider.com - February 18 at 3:35 PM

Social

Chart

ArQule (ARQL) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff